EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseSystematische Übersicht

New and Emerging Pharmacotherapies for Pruritus: A Systematic Review and Network Meta-Analysis

Han Li, Anita Arthur, Mahtab Forouzandeh, Ariel Pomputius, Lyda Cuervo-Pardo, Marjorie Montanez-Wiscovich iD

Dermatitis® · 01.07.2025 · 36 (4) · 333-342

DOI: 10.1089/derm.2023.0419 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift Dermatitis®, online erschienen am 22.07.2025. Verfasst von Han Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: From the University of Florida College of Medicine, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Dermatologic Agents, Pruritus. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic pruritus, a common symptom of dermatologic diseases, impairs quality of life. No review exists that evaluates the efficacy of emerging therapies based on a single standardized scale. We assessed efficacy and adverse effects of novel treatments available for pruritus in patients diagnosed with common pruritic diseases using the proportions of patients experiencing a ≥4-point reduction as a standardized efficacy measure between studies. We searched PubMed, Web of Science, Embase, and Cochrane Central Register of Controlled Trials for phase II or III trials reporting change in numerical rating scale following interventions for pruritus from 2015 to 2023. The strongest improvements in pruritus were seen from ustekinumab (RR 4.30 [2.88; 6.41]) and ixekizumab (RR 4.42 [3.32; 5.88]) for psoriasis and upadacitinib (RR 5.54 [95% CI: 4.53–6.78]), abrocitinib (RR 3.76 [95% CI: 2.97–4.76]), and baricitinib (RR 3.63 [95% CI: 2.36–5.58]) for atopic dermatitis. Nemolizumab (RR 3.06 [95% CI: 1.63–5.74]) and dupilumab (RR 2.11 [95% CI: 1.30–3.41]) were most effective for prurigo nodularis, though fewer studies were available for comparison. Adverse effects were mild and similar between agents; discontinuation rates were low. This review evaluates efficacy of emerging pruritus treatments based on a single standardized measurement, highlighting the role of novel agents in the treatment of chronic pruritus.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatologic AgentsPruritusHumansAntibodies, Monoclonal, HumanizedAzetidinesBenzimidazolesHeterocyclic Compounds, 3-RingPsoriasisPurinesPyrazolesPyrimidinesSulfonamidesUstekinumab

Substanzen

abrocitinibAntibodies, Monoclonal, HumanizedAzetidinesbaricitinibBenzimidazolesDermatologic AgentsdupilumabHeterocyclic Compounds, 3-RingixekizumabPurines

Autor:innen und Institutionen

  • From the University of Florida College of Medicine, Gainesville, Florida, USA.
  • Department of Dermatology, University of Florida College of Medicine, Gainesville, Florida, USA.
  • University of Florida Health Science Center Libraries, Gainesville, Florida, USA.
  • Division of Rheumatology, Allergy & Clinical Immunology, Department of Medicine, University of Florida, Gainesville, Florida, USA.

ORCID-Profile: Marjorie Montanez-Wiscovich

Zitieren

APA

Li, H., Arthur, A., Forouzandeh, M., Pomputius, A., Cuervo-Pardo, L., & Montanez-Wiscovich, M. (2025). New and Emerging Pharmacotherapies for Pruritus: A Systematic Review and Network Meta-Analysis. Dermatitis®, 36(4), 333-342. https://doi.org/10.1089/derm.2023.0419

Vancouver

Li H, Arthur A, Forouzandeh M, Pomputius A, Cuervo-Pardo L, Montanez-Wiscovich M. New and Emerging Pharmacotherapies for Pruritus: A Systematic Review and Network Meta-Analysis. Dermatitis®. 2025;36(4):333-342. doi:10.1089/derm.2023.0419

BibTeX
@article{Li2025,
  author = {Li, Han and Arthur, Anita and Forouzandeh, Mahtab and Pomputius, Ariel and Cuervo-Pardo, Lyda and Montanez-Wiscovich, Marjorie},
  title = {New and Emerging Pharmacotherapies for Pruritus: A Systematic Review and Network Meta-Analysis},
  journal = {Dermatitis®},
  year = {2025},
  volume = {36},
  number = {4},
  pages = {333--342},
  doi = {10.1089/derm.2023.0419}
}
Kostenlos starten →